I recently sat down with one of the leading Medical Directors in Japan to discuss the critical evolution of the Medical Science Liaison (MSL) role.
The MSL has transformed from a scientific resource into a strategic partner essential for successful product launches and market integration. In today’s competitive landscape, simply possessing deep scientific knowledge is no longer enough. The highest-performing MSLs demonstrate a crucial “commercial mindset”— an ability to translate scientific expertise into measurable, strategic engagement.
When assessing talent, we focus on two critical, objective pillars that separate high-impact MSLs from the rest: Strategic Territory Architecting and Purposeful HCP Engagement.
Pillar One: Strategic Territory Architecting
A high-impact MSL doesn’t just manage a territory; they architect it. Their effectiveness is fundamentally tied to how strategically they plan their activities, ensuring every effort maximizes influence and efficiency. We look for candidates who demonstrate mastery in the following areas:
1. Targeting and Prioritization
The true metric of success isn’t the number of meetings held, but the depth of engagement with the right Healthcare Professionals (HCPs).
- Influence Mapping: How does the MSL move beyond traditional metrics to identify and prioritize Key Opinion Leaders (KOLs)? This requires understanding true clinical influence, adoption patterns, and research interests. The goal is strategic engagement, not volume.
- Operational Efficiency: We assess their ability to build efficient schedules. This includes evidence of planning mastery, such as grouping meetings geographically, leveraging digital tools for remote interactions, and proficiently using a CRM system to track, manage, and analyze stakeholder interactions.
2. Internal Network and Cross-Functional Leverage
The MSL sits at the intersection of Medical, Commercial, and R&D. Their success often depends on their ability to manage and leverage these internal relationships.
- Cross-Functional Partnership: Does the MSL actively seek to leverage the Medical Representative (MR) network? We assess their ability to gain access to physicians, gather pre-call insights, and align on non-scientific goals—all while strictly maintaining compliance boundaries. MSLs with a strong partnership mindset with the Commercial team consistently outperform those who don’t. A true partnership ensures everyone is working toward the single goal of supporting patients.
Pillar Two: Purposeful HCP Engagement
Every successful MSL conversation has a clear, strategic objective aimed at advancing the HCP’s understanding along a defined pathway. We evaluate a candidate’s ability to structure their dialogue to systematically move an HCP from initial awareness to clinical expertise.
It’s common for MSLs to be excellent at analyzing complex scientific data yet struggle to analyze their own interaction data to find areas for improvement. Regular capability building workshops have been key to improving the quality and strategic direction of these interactions.
This process is typically executed across three phases:
Phase A: Awareness (Establish Value and Need)
The initial objective is to establish the MSL’s value and introduce the drug’s core concept by focusing on the HCP’s perspective.
- Understanding the Gap: Can the MSL quickly initiate a conversation by first understanding the HCP’s current knowledge of the therapeutic area and their unmet needs? This initial exchange must be highly relevant and tailored, acting as a “hook” that justifies the clinician’s precious time. I once joined an MSL call where the MSL kept talking about the new medicine while the HCP focused on the challenges of using the established standard of care. A great MSL would listen, pick up the conversation from the HCP’s point of view, and tailor the information based on where the HCP is right now.
Phase B: Understanding (Communicate Core Science)
This phase focuses on communicating the complex scientific concepts in an accessible manner.
- Clarity and Resonance: We evaluate the MSL’s ability to explain the drug’s Mechanism of Action (MOA), efficacy, and safety profile in a clear, digestible manner that resonates with the clinician’s busy practice. They must be able to anticipate common objections and simplify complexity without losing scientific fidelity.
Phase C: Expert (Strategic Insight and Peer Status)
The ultimate goal is to transition the HCP from a basic understanding to a peer-level expert who actively champions the data and insights.
- Comprehensive Communication: How does the MSL plan to use Real-World Evidence (RWE), head-to-head data, or competitor data to address highly specific clinical challenges or answer nuanced questions? An expert MSL doesn’t just deliver data; they facilitate a strategic dialogue that positions the clinician as a deep thinker in the therapeutic space, leading to a true scientific partnership.
By focusing on these objective criteria—strategic planning, communication effectiveness, and the purposeful use of scientific information—Medical Affairs leaders can ensure they are building a team of MSLs who are not just excellent communicators, but high-impact strategic contributors to the entire organization.
If your organization is looking to build or strengthen a high-impact MSL team, now is the time to focus on these strategic competencies—not just scientific credentials. Let’s explore how we can help you identify and develop MSL talent that drives real market impact.
Book a discovery call
